Se-Hee Son1, Young-Hwa Goo1, Mihyun Choi1, Pradip K Saha2, Kazuhiro Oka2, Lawrence C B Chan2, Antoni Paul3. 1. Center for Cardiovascular Sciences, Albany Medical College, 47 New Scotland Avenue, MC-8, Albany, NY 12208, USA. 2. Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 3. Center for Cardiovascular Sciences, Albany Medical College, 47 New Scotland Avenue, MC-8, Albany, NY 12208, USA paula@mail.amc.edu.
Abstract
AIMS: Atherosclerosis development can be ameliorated by promoting reverse cholesterol transport (RCT) from arteries. The process involves cholesterol efflux from foam cells to extracellular acceptors such as apolipoprotein A-I (apoA-I) and high-density lipoprotein (HDL) that mediate transport to the liver. Perilipin-2 (PLIN2) is a lipid droplet (LD)-associated protein that in macrophages facilitates cholesterol storage and prevents efflux. We hypothesized that atheroprotection would be enhanced by concurrently targeting PLIN2 to increase the efflux capacity of foam cells and increasing plasma apoA-I and HDL. METHODS AND RESULTS: PLIN2-knockout and wild-type mice lacking apolipoprotein E (PLIN2(-/-)/apoE(-/-) and PLIN2(+/+)/apoE(-/-)) were treated with a helper-dependent adenoviral vector encoding human apoA-I (HDAd-AI) or with control empty vector. Treatment with HDAd-AI increased hepatic apoA-I production, plasma apoA-I and HDL-cholesterol (HDL-C), and apoA-I deposition in lesions to a similar extent in PLIN2(-/-)/apoE(-/-) and PLIN2(+/+)/apoE(-/-) mice. However, atherosclerosis development at the aortic sinus was considerably lower in HDAd-AI-treated PLIN2(-/-)/apoE(-/-) mice. A more stable lesion phenotype, with increased collagen content, was primarily associated to treatment with HDAd-AI, but was enhanced under PLIN2 deficiency. PLIN2 deficiency and apoA-I cumulatively reduced LDs and cholesterol ester content in cultured macrophages. Neutral lipid in atheroma was significantly reduced in HDAd-AI-treated PLIN2(-/-)/apoE(-/-) mice, and RCT from macrophages to feces was enhanced in PLIN2(-/-) macrophages. CONCLUSION: These studies demonstrate a mutually beneficial relationship between PLIN2 deficiency and elevated apoA-I/HDL-C in preventing atherosclerosis development. The data support that targeting foam cell components to mobilize cholesterol may be a promising strategy to enhance the atheroprotection of plasma cholesterol acceptors. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Atherosclerosis development can be ameliorated by promoting reverse cholesterol transport (RCT) from arteries. The process involves cholesterol efflux from foam cells to extracellular acceptors such as apolipoprotein A-I (apoA-I) and high-density lipoprotein (HDL) that mediate transport to the liver. Perilipin-2 (PLIN2) is a lipid droplet (LD)-associated protein that in macrophages facilitates cholesterol storage and prevents efflux. We hypothesized that atheroprotection would be enhanced by concurrently targeting PLIN2 to increase the efflux capacity of foam cells and increasing plasma apoA-I and HDL. METHODS AND RESULTS: PLIN2-knockout and wild-type mice lacking apolipoprotein E (PLIN2(-/-)/apoE(-/-) and PLIN2(+/+)/apoE(-/-)) were treated with a helper-dependent adenoviral vector encoding human apoA-I (HDAd-AI) or with control empty vector. Treatment with HDAd-AI increased hepatic apoA-I production, plasma apoA-I and HDL-cholesterol (HDL-C), and apoA-I deposition in lesions to a similar extent in PLIN2(-/-)/apoE(-/-) and PLIN2(+/+)/apoE(-/-) mice. However, atherosclerosis development at the aortic sinus was considerably lower in HDAd-AI-treated PLIN2(-/-)/apoE(-/-) mice. A more stable lesion phenotype, with increased collagen content, was primarily associated to treatment with HDAd-AI, but was enhanced under PLIN2 deficiency. PLIN2 deficiency and apoA-I cumulatively reduced LDs and cholesterol ester content in cultured macrophages. Neutral lipid in atheroma was significantly reduced in HDAd-AI-treated PLIN2(-/-)/apoE(-/-) mice, and RCT from macrophages to feces was enhanced in PLIN2(-/-) macrophages. CONCLUSION: These studies demonstrate a mutually beneficial relationship between PLIN2 deficiency and elevated apoA-I/HDL-C in preventing atherosclerosis development. The data support that targeting foam cell components to mobilize cholesterol may be a promising strategy to enhance the atheroprotection of plasma cholesterol acceptors. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: YuZhen Zhang; Jaqueline R Da Silva; Muredach Reilly; Jeffrey T Billheimer; George H Rothblat; Daniel J Rader Journal: J Clin Invest Date: 2005-10 Impact factor: 14.808
Authors: Miranda Van Eck; Roshni R Singaraja; Dan Ye; Reeni B Hildebrand; Erick R James; Michael R Hayden; Theo J C Van Berkel Journal: Arterioscler Thromb Vasc Biol Date: 2006-02-02 Impact factor: 8.311
Authors: E J Schaefer; S Lamon-Fava; J M Ordovas; S D Cohn; M M Schaefer; W P Castelli; P W Wilson Journal: J Lipid Res Date: 1994-05 Impact factor: 5.922
Authors: Emily E Morin; Yanhong Guo; Hongliang He; Wenmin Yuan; Whitney N Souery; Maria V Fawaz; Yuqing Eugene Chen; Anna Schwendeman Journal: Front Pharmacol Date: 2020-12-16 Impact factor: 5.810
Authors: Mariana G Figueiro; Young-Hwa Goo; Ryan Hogan; Barbara Plitnick; Jeong-Kyung Lee; Kiran Jahangir; Mousumi Moulik; Vijay K Yechoor; Antoni Paul Journal: J Am Heart Assoc Date: 2021-01-06 Impact factor: 5.501
Authors: Jaume Amengual; Yoscar Ogando; Cyrus Nikain; Alexandra Quezada; Kun Qian; Tomas Vaisar; Edward A Fisher Journal: Mol Pharmacol Date: 2020-12-31 Impact factor: 4.436
Authors: Pengpeng Zhang; Lian Meng; Lingxie Song; Juan Du; Shutong Du; Wenwen Cui; Chunxia Liu; Feng Li Journal: Curr Genomics Date: 2018-05 Impact factor: 2.236